Lexeo Therapeutics, Inc. (LXEO) Receives a Buy from Oppenheimer

Oppenheimer analyst Leland Gershell maintained a Buy rating on Lexeo Therapeutics, Inc. today and set a price target of $20.00. The company’s shares closed yesterday at $8.34.

Elevate Your Investing Strategy:

• Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

According to TipRanks, Gershell is a 3-star analyst with an average return of 1.3% and a 38.66% success rate. Gershell covers the Healthcare sector, focusing on stocks such as Avalo Therapeutics, Rhythm Pharmaceuticals, and Argenx Se.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Lexeo Therapeutics, Inc. with a $18.40 average price target, representing a 120.62% upside. In a report released yesterday, Chardan Capital also maintained a Buy rating on the stock with a $17.00 price target.

LXEO market cap is currently $349.4M and has a P/E ratio of -2.56.

Based on the recent corporate insider activity of 32 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of LXEO in relation to earlier this year. Most recently, in August 2025, Jenny Robertson, the CLO of LXEO sold 542.00 shares for a total of $2,525.72.